The global immunotherapy drugs market size accounted for USD 270.2 billion in 2024, grew to USD 318.83 billion in 2025 and is projected to surpass around USD 1,414.16 billion by 2034, representing a healthy CAGR of 18% between 2024 and 2034. The North America immunotherapy drugs market size is calculated at USD 124.29 billion in 2024 and is expected to grow at a fastest CAGR of 18.12% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunotherapy Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunotherapy Drugs Market, by Drug Type, 2024-2034
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Interleukins
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Interferons Alpha & Beta
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Immunotherapy Drugs Market, by Therapeutic Area, 2024-2034
9.1.1. Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Infectious Diseases
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Autoimmune & Inflammatory Diseases
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug (2021-2034)
10.1.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug (2021-2034)
10.2.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug (2021-2034)
10.5.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
11.1. F. Hoffmann-La Roche AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. GlaxoSmithKline plc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. AbbVie, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Amgen, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Merck & Co., Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Alligator Bioscience
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. UbiVac
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis International AG
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AstraZeneca plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample